Effect of Intravitreal Bevacizumab on Corneal Endothelium
试验速览
- 阶段
- 不适用
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- Corneal endothelium cell change after intravitreal Bevacizumab injection
研究概览
简要总结
To evaluate corneal endothelium cell change after intravitreal Bevacizumab injection
详细描述
Intravitreal Bevacizumab has been used by retinal specialist in treatment many retinal diseases. Although it not approved by FDA for treatment. In many In vitro studies, its showed saftey in the eyes especially for corneal endothelium cells, that important cells to keep cornea clear. This study use Confoscan-Corneal confocal microsope to evaluate corneal endothelium before and after intravitreal Bevacizumab injection in routine retinal disease at 6 month follow up.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •aged between 20 and 80 years old
- •can come to regular follow up at 6 month
- •signed written consent forms
- •not have corneal scar, or glaucoma
- •history of treatment with laser or anti-VEGF therapy in 3 month prior to recruit
- •high risk in cerebrovascular and cardiovascular diseases
- •Pregnancy and breastfeeding
- •can undergo confocal microspopy
排除标准
- •History of intraocular surgery or ocular trauma during study
结局指标
主要结局
Corneal endothelium cell change after intravitreal Bevacizumab injection
时间窗: 6 months
Measure the corneal endothelium cell using Confoscan4-Corneal confocal microscope in patient in retinal vascular clinic before and after treat with intravitreal Bevacizumab
次要结局
- Assess the complication after intravitreal Bevacizumab injection(6 month)
研究者
Kasem Yospaiboon
Kasem Yospaiboon, MD
Khon Kaen University